Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial

Journal of Human Hypertension

Volumn 29, Issue 1, 2015, Pages 22-27

  Gueyffier, F ^a,b,c   Subtil, F ^a,b,c   Bejan Angoulvant, T ^d   Zerbib, Y ^c,e   Baguet, J P ^f,g   Boivin, J M ^h   Mercier, A ^i,j   Leftheriotis, G ^k   Gagnol, J P ^l   Fauvel, J P ^m   Giraud, C ^a,b,c   Bricca, G ⁿ   Maucort Boulch, D ^a,c   Erpeldinger, S ^c  

^a HOSPICES CIVILS DE LYON   (France)

^b LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e University Claude Bernard   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g Université Grenoble Alpes   (France)

^h UNIVERSITÉ DE LORRAINE   (France)

ⁱ UNIVERSITÉ DE ROUEN   (France)

^j ROUEN UNIVERSITY HOSPITAL   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l HÔPITAL ARNAUD DE VILLENEUVE   (France)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ CROIX ROUSSE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INDAPAMIDE; PERINDOPRIL; PLACEBO; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGE DETERMINATION; AGED; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SLOW RELEASE FORMULATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AGE; CLINICAL TRIAL; DRUG EFFECTS; FRANCE; PATHOPHYSIOLOGY; PATIENT SELECTION; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; FRANCE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PATIENT SELECTION; PERINDOPRIL; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928651022     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.29     Document Type: Article

References (18)

1. Mancia G, Laurent S, Agabati RE, Ambrosioni E, Burnier M, Caufield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
2. http://www.sfhta.eu/wp-content/uploads/2012/12/Recommandation-SFHTA-2013-Prise-en-charge-HTA-de-lAdulte.pdf.
3. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 2012; 8(Art. No.): CD006742.
4. Hansson L, Zanchetti A, Carruthers SG, Dahlhöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
5. Boissel JP, Gueyffier F, Boutitie F, Pocock S, Fagard R. Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fund Clin Pharmacol 2005; 19: 579-584.
6. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315.
7. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
8. Wu Y, Li YS, Bejan-Angoulvant T, Gueyffier F. Modeling of systolic blood pressure reaction to antihypertensive agents in people with hypertension. Zhonghua Xin Xue Guan Bing Za Zh, i 2011; 39: 309-314.
9. Bejan-Angoulvant T, Baguet JP, Erpeldinger S, Boivin JM, Mercier A, Leftheriotis G et al. The IDEAL study: towards personalized drug treatment of hypertension. Therapie 2012; 67: 1-10.
10. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995; 8: 189-192.
11. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994; 12: 1053-1060.
12. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-2013.
13. Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (the GENRES Study). Am J Hypertens 2007; 20: 311-318.
14. Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T et al. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens 2008; 26: 1250-1256.
15. Suonsyrjä T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K, Hiltunen TP. Common genetic variation of b1-and b2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics 2010; 20: 342-345.
16. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
17. Riley RD, Lambert PC, Staessen JA, Thijs L, Wang J, Gueyffier F et al. Combining individual patient data and aggregate data in meta-analysis of continuous outcomes. Stat Med 2008; 28: 1870-1893.
18. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Fox KM et al. Monitoring initial response to angiotensin-converting enzyme inhibitor-based regimens. An individual patient data meta-analysis from randomized, placebo-controlled trials. Hypertension 2010; 56: 533-539.